aplaviroc

Also known as AK-602, GW 873140, GW873140A

Aplaviroc (INN, codenamed AK602 and GSK-873140) is a CCR5 entry inhibitor that belongs to a class of 2,5-diketopiperazines developed for the treatment of HIV infection. It was developed by GlaxoSmithKline.

Wikidata facts

Mass: 577.315

Show 4 more facts

chemical formula: C₃₃H₄₃N₃O₆
canonical SMILES: CCCCN1C(=O)C(NC(=O)C12CCN(CC2)CC3=CC=C(C=C3)OC4=CC=C(C=C4)C(=O)O)C(C5CCCCC5)O
isomeric SMILES: CCCCN1C(=O)[C@H](NC(=O)C12CCN(CC2)CC3=CC=C(C=C3)OC4=CC=C(C=C4)C(=O)O)[C@@H](C5CCCCC5)O
Commons category: Aplaviroc

Sources (3)

via Wikidata · CC0

~2 min read

Article

3 sections

Contents

See also
References
Further reading

{{Infobox drug | verifiedrevid = 451871816 | IUPAC_name = 4-(4-{[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo- 1,4,9-triazaspiro[5.5]undecan-9-yl]methyl}phenoxy)benzoic acid | image = Aplaviroc structure.svg | image_class = skin-invert-image | width = 300

| pregnancy_category = | legal_status = Development terminated | routes_of_administration = Oral